Dr. Kumar’s Take
The source here is a narrative review article from the Journal of Lipid and Atherosclerosis, not a network meta-analysis of outcome trials. It walks through what the guidelines now recommend when a statin alone is not enough: add ezetimibe first, and if the LDL target is still out of reach on a maximally tolerated statin plus ezetimibe, consider a PCSK9 inhibitor. That sequence matches how I think about these drugs in practice. Statins do the heavy lifting, dropping LDL cholesterol by up to 50% from baseline depending on potency and cutting ASCVD risk by 15% to 37%. The add-on agents exist because a real residual risk remains after that, not because they replace the statin.
Brief Summary:
This is a review article on pharmacological strategies for dyslipidemia beyond statins, focused on two agents that recent American, European, and Korean guidelines endorse as add-on therapy: ezetimibe and the PCSK9 inhibitors alirocumab and evolocumab. The authors summarize the guideline targets, the mechanism of each drug, and the trial evidence behind them. Ezetimibe added to a statin gives further LDL cholesterol reduction and lowers ASCVD risk without raising significant safety concerns. PCSK9 inhibitors significantly lower serum LDL cholesterol and ASCVD risk when added to maximally tolerated statin therapy, with the drawbacks of high cost and adverse events such as injection site reactions.
Key Takeaways:
✔ Guideline targets: for patients with a history of ischemic heart disease or stroke, the goal is an LDL cholesterol level below 70 mg/dL or a reduction of at least 50% from baseline. The Korean guideline revised in 2018 sets the same target for extremely high risk patients.
✔ Ezetimibe as monotherapy reduced LDL cholesterol by about 18% in patients with dyslipidemia.
✔ Ezetimibe added to a statin gave a further 15% to 20% LDL reduction, for a total reduction of 34% to 61%.
✔ IMPROVE-IT, a double-blind randomized trial in 18,144 patients with acute coronary syndrome, found that adding ezetimibe to simvastatin lowered LDL cholesterol by 24% and produced a 2% lower rate of the primary composite endpoint compared with simvastatin alone.
✔ PCSK9 inhibitors are reserved for patients who cannot reach LDL targets on a maximally tolerated statin plus ezetimibe.
Study Design:
This is a narrative review article, not a trial and not a pooled statistical analysis. The authors reviewed the 2018 AHA/ACC guideline, the 2016 ESC/EAS guideline, and the 2018 Korean dyslipidemia guideline, then summarized the clinical trial evidence for the two non-statin agents those guidelines recommend:
- PCSK9 inhibitors (alirocumab, evolocumab)
- Ezetimibe
The one pooled analysis the review describes is a 2015 study of ezetimibe add-on therapy covering 27 different trials, which showed a significant LDL cholesterol lowering effect compared with statin monotherapy.
Results:
✔ LDL cholesterol lowering:
- Statins alone reduce serum LDL cholesterol by up to 50% from baseline according to potency, and reduce ASCVD risk by 15% to 37%.
- Ezetimibe alone reduced LDL cholesterol by 18%; added to a statin it added another 15% to 20%, for a total of 34% to 61%.
✔ Cardiovascular events in IMPROVE-IT:
- In 18,144 patients with acute coronary syndrome, ezetimibe plus simvastatin lowered LDL cholesterol by 24% and reduced the composite primary endpoint rate by 2% versus simvastatin alone (p<0.05).
- That composite endpoint included cardiovascular death, nonfatal myocardial infarction, hospitalization for unstable angina, coronary revascularization, and nonfatal stroke.
✔ Positioning:
- Ezetimibe is indicated for high cardiovascular risk patients whose LDL cholesterol stays high despite a high intensity or maximum tolerated statin dose.
- Ezetimibe combined with a mild to moderate intensity statin is also used when a patient has statin-associated adverse effects such as myalgia, and that combination is relatively safer.
How PCSK9 Inhibitors and Ezetimibe Work:
Ezetimibe targets the Niemann-Pick C1-like 1 (NPC1L1) protein, blocking the absorption of cholesterol from the intestine and thereby lowering LDL cholesterol. PCSK9 inhibitors are monoclonal antibodies against proprotein convertase subtilisin/kexin type 9; alirocumab and evolocumab are approved to lower LDL cholesterol. Statins work differently again, blocking the cholesterol synthesis pathway in the liver by inhibiting HMG-CoA reductase. High LDL cholesterol is a well established risk factor for atherosclerotic cardiovascular disease, which remains the leading cause of death worldwide.
Related Studies and Research
PCSK9 Inhibitors and Cardiovascular Risk. Explores how PCSK9 inhibitors lower LDL cholesterol and reduce cardiovascular risk.
ApoB vs. LDL Cholesterol: Which is the Better Risk Marker?. Compares ApoB and LDL cholesterol as predictors of cardiovascular disease.
Statins and Heart Disease: A Review. Examines the role of statins in managing heart disease and their overall effectiveness.
Rosuvastatin, CRP, and the JUPITER Trial. Reviews how rosuvastatin and CRP levels influenced cardiovascular risk reduction in the JUPITER trial.
Frequently Asked Questions
What is residual cholesterol risk?
Even on high intensity statin therapy, which lowers both LDL cholesterol and cardiovascular events, patients with established atherosclerotic cardiovascular disease still have recurrent events. The review calls that leftover risk residual cholesterol risk, and it is the reason the guidelines add a second drug rather than simply pushing the statin dose higher.
What LDL cholesterol number should I be aiming for?
The review notes that many studies suggest an ideal total cholesterol of about 150 mg/dL and LDL cholesterol at or below 100 mg/dL. If you have a history of ischemic heart disease or stroke, the target drops below 70 mg/dL, or a reduction of at least 50% from your baseline.
In what order are these drugs added?
Statin first, with dose escalation to reach the target. If LDL cholesterol stays high on a high intensity or maximum tolerated statin dose in a high risk patient, ezetimibe is added. If the target still is not reached on maximum tolerated statin plus ezetimibe, a PCSK9 inhibitor can be considered.
What if I cannot tolerate a statin?
Ezetimibe combined with a mild to moderate statin intensity is used when patients have statin-associated adverse effects such as myalgia, and the review describes that combination as relatively safer.
What are the downsides of PCSK9 inhibitors?
High cost, and adverse events such as injection site reactions.
Conclusion
This review makes the case for a stepped approach rather than a single drug. Statins remain first-line for both primary and secondary prevention of atherosclerotic cardiovascular disease, but they do not get everyone to target and they leave a residual risk of events. Ezetimibe added to a statin lowers LDL cholesterol further and reduces ASCVD risk without significant safety concerns, and in IMPROVE-IT that translated into a 2% lower rate of the composite endpoint in patients with acute coronary syndrome. PCSK9 inhibitors sit one step further along, for patients still above target on maximally tolerated statin plus ezetimibe. If you have established cardiovascular disease and your LDL cholesterol is above 70 mg/dL on your current statin, that is the conversation to have with your physician.
